 |
Online Review #5
Systemic chemotherapy is one of the standard treatments for the roughly 80% of patients with hepatocellular carcinoma (HCC) who are not candidates for curative surgery. Hepatitis B infection, a leading causative factor for this aggressive form of cancer, is present in 85% of Southeast Asian and Chinese patients with HCC. This online review will help you to better identify prognostic factors (specifically HBV DNA viral loads) that affect survival and the development of treatment-induced hepatitis in patients with HCC who are undergoing systemic chemotherapy. Expert commentary from W. Ray Kim, MD, is also provided. This online review represents Course 7 of Advanced Certificate Program III: Bridging Cultural Differences to Improve HBV Treatment in Asian and Other Diverse Communities. |
 |
Online Podcast
In this lively podcast interview, Adrian M. Di Bisceglie, MD, FACP, George K.K. Lau, MD, and Mindie Nguyen, MD, MAS, explore several obstacles in diagnosing and treating HBV in Asian-American patients. Among the barriers discussed, along with suggestions for overcoming these challenges, are the communication difficulties involved in treating non-English speaking patients, patient reliance on traditional herbal treatments, patient reluctance to undergo certain diagnostic procedures, and obtaining treatment for uninsured patients. This podcast represents Course 6 of Advanced Certificate Program III: Bridging Cultural Differences to Improve HBV Treatment in Asian and Other Diverse Communities. |
 |
Online Tx Reporter #1
In this online case-based Tx Reporter newsletter, George K.K. Lau, MD, explores the case of a patient born in Hong Kong and now living in San Francisco. Following the patient from diagnosis through 2 years of treatment, Dr. Lau demonstrates the importance of screening in this patient population as well as the role of genotype and HBV DNA levels in making management decisions. This online newsletter represents Course 5 of Advanced Certificate Program III: Bridging Cultural Differences to Improve HBV Treatment in Asian and Other Diverse Communities. |
On-Demand Webcast |
On-Demand Webcast
This CME on-demand webcast, Hepatitis C: From Scientific Foundations to New Vistas in Treatment, explores what is known about viral and host factors, including the immune system, and how these factors influence response and inform new directions in therapy. Each of the four presentations is founded on in-depth scientific content and clinical immediacy. Our expert faculty, comprised of scientists and practitioners, invite you to expand your knowledge of hepatitis C and its treatment. |
 |
Online Review #4
Many people of Asian or Pacific Island descent are at increased risk for developing chronic hepatitis B virus (HBV) infection because the virus is endemic in their countries of origin. Compounding problems, some people with chronic HBV infection remain asymptomatic carriers of the disease for many years. In this article review, Adrian M. Di Bisceglie, MD, FACP, examines the current incidence and any causal factors of spontaneous HBsAG seroclearance in a high-risk Asian American population, which will help improve the accuracy of HBV screening. This online review is part of the Advanced Certificate Program III: Bridging Cultural Differences to Improve HBV Treatment in Asian and Other Diverse Communities. |
 |
Online Posting #3
Asian Americans and recent immigrants from Pacific Rim nations with high HBV endemicity have heightened risk for developing HBV infection and liver cancer. Many, including the Chinese, are also carriers of chronic HBV. The study reviewed in this posting identifies a clear need to improve awareness among healthcare providers of the need to screen, and will also help identify the serologic tests that should be implemented routinely in these high-risk populations. This online posting represents Course 3 of Advanced Certificate Program III: Bridging Cultural Differences to Improve HBV Treatment in Asian and Other Diverse Communities. |
 |
Online Posting #2
Some Asian Americans, particularly recent immigrants who were born in countries of high HBV endemicity, are at increased risk for liver cancer. This online posting, which features expert insights from Mindie Nguyen, MD, MAS, will help you identify those at greatest risk as well as some of the barriers these individuals face in accessing healthcare. This online posting represents Course 2 of Advanced Certificate Program III: Bridging Cultural Differences to Improve HBV Treatment in Asian and Other Diverse Communities. |
 |
Online Posting #1
W. Ray Kim, MD, examines the key findings and final recommendations from a recent NIH-sponsored clinical research workshop that surveyed the current understanding of hepatitis B. This online posting represents Course 1 of Advanced Certificate Program III: Bridging Cultural Differences to Improve HBV Treatment in Asian and Other Diverse Communities. |
Certificate Program |
Certificate Program
Adrian M. Di Bisceglie, MD, FACP, and Robert G. Gish, MD, co-chair this free, yearlong CME/CE program offering the latest information on chronic hepatitis B virus (HBV) infection. Curriculum topics include screening, genotyping, testing for antiviral-resistance mutations, treatment guidelines (updates from AASLD, EASL, and DDW), current and emerging HBV treatment options, consolidation therapy, HIV/HCV coinfection, cirrhosis, and cultural/communications barriers to diagnosis and treatment. Learn more and enroll today! |
Journal Supplement |
Journal Supplement
Mark S. Sulkowski, MD, and a team of expert faculty contributors discuss the management of HBV, HCV, and cirrhosis in HIV-infected patients in this supplement to the Journal of Acquired Immune Deficiency Syndromes (Volume 45, Supplement 2, July 1, 2007). Order your free copy of this important and informative journal supplement today! |
On-Demand Webcast |
On-Demand Webcast—Available Now!
The times, they are a-changin'—so is the way we manage HCV infection. Join us as we examine the future direction of anti-HCV therapy and help clinicians embrace the changes ahead.
|
Audioconference |
On-Demand Webcast—Available Now!
Kris V. Kowdley, MD, reviews the updated HBV treatment guidelines, recent FDA-approved anti-HBV agents, and the newest data regarding use of lamivudine, adefovir, entecavir, peginterferon, and telbivudine in this on-demand webcast of the live February 13 phone conference. Selecting an appropriate antiviral agent and adjusting treatment as needed based on response and potential development of resistance are also discussed. Webcast features: recorded Q&A session, and downloadable slides and syllabus.
|
On-Demand Webcast |
On-Demand Webcast—Now Available!
This 1-hour, CME/CE Webcast, Expert Perspectives on Hepatitis B Virus and the Infected Patient, is led by Dr. Adrian M. Di Bisceglie, and will provide you with a solid overview of the virus, including its structure and replication, genotypes, and natural history. Then we will talk about how to make optimal use of available screening and diagnostic tools, as well as how to apply recently updated management guidelines to determine which patients are candidates for treatment.
|
4 Daily Podcasts |
This activity has reached its termination date and no longer offers continuing education credit.
4 Daily Podcasts
Daily Podcasts on HBV and HCV, a series of four lively 15-minute audio interviews, features commentary by top gastroenterology and hepatology experts recorded onsite at the 2006 meeting in Boston. Leading experts provide insights on the latest clinical studies and scientific advances related to HBV and HCV.
|
Audio with Slides |
This activity has reached its termination date and no longer offers continuing education credit.
Audio with Slides — From the satellite symposium presented at the 2006 Meeting in Boston
The faculty of Revolutionizing the Way We Treat HCV: STAT-C will lead you through a clinical and scientific assessment of these new agents. Drawing on decades of expertise in clinical and research virology, gastroenterology and hepatology, Drs. Jacobson, Rice, Pawlotsky, and McHutchison will examine the molecular foundation for the design of STAT-C agents, identifying methodology to define and quantify resistance, presenting the most recent efficacy, safety, and resistance data, and projecting the implications of these developments within the context of your clinical practice.
|
On-Demand Webcast |
This activity has reached its termination date and no longer offers continuing education credit.
On-Demand Webcast
This 1-hour webcast, led by Robert G. Gish, MD, and W. Ray Kim, MD, focuses on why it is important for clinicians to collaborate in order to optimize the management of patients with HBV infection. Covered topics include screening and testing patients, identifying candidates for therapy, evaluating treatment options based on current guidelines and available agents, as well as monitoring and follow-up care. Presentation slides and syllabus are also available for download. The webcast concludes with the Q&A session from the live audioconference.
|
Audio-CD with Slides |
This activity has reached its termination date and no longer offers continuing education credit.
Audio-CD with Slides
Transforming Anti-HCV Treatment: The Potential for Specifically Targeted Antiviral Therapy for HCV (STAT-C) brings you the audio presentations from the satellite symposium held at the 12th International Symposium on Viral Hepatitis and Liver Disease (ISVHLD) on July 2, 2006, in Paris. In this free online CME activity, which includes downloadable slides and syllabus, our expert faculty provides the latest safety, efficacy, and resistance data of VX-950, SCH 503034, and NM-283, and also discusses how these new agents will change our current therapeutic strategies.
|
Tx Reporter Series |
Tx Reporter Series &mdash Parts 1–5 Now Available!
This 5-part series describes the latest research on current and emerging therapeutic agents to help clinicians devise optimal treatment strategies for patients infected with hepatitis B virus.
|
Certificate Program II |
Certificate Program II
This free, web-based educational program is designed to provide up-to-date, state-of-the-science information on the management of hepatitis B, including the natural history and epidemiology of the virus, determining which patients to treat, selecting the most appropriate course of therapy, and patient management challenges.
|
Audio Interviews |
Audio Interviews
Newsmakers In Medicine™ is designed for primary care physicians and other clinicians who need rapid and convenient access to state-of-the-science data and practical insights on important clinical topics. This 9-part series of 15-minute audio interviews conducted with experts on infectious diseases explores the growing prevalence of hepatitis A and hepatitis B virus infections and provides cutting-edge information about prevention through vaccination.
|
HBV Monthly Posting |
HBV Monthly Posting
This course is part of Advanced Certificate Program II: Management of Chronic Hepatitis B, featuring short case studies focusing on treatment strategies and challenges clinicians face in managing patients with HBV. The case studies will be posted once a month, and you can earn continuing education credit by taking the posttest. This course also offers an "Ask the Experts" forum where you can ask the "Faculty of the Month" questions about the postings contained on this website.
|
On-Demand Webcast |
This activity has reached its termination date and no longer offers continuing education credit.
On-Demand Webcast
Our expert faculty of Expert Perspectives: Refining the HBV Treatment Paradigm understand what is important to the practicing physician. Together we'll help you integrate the latest scientific advances into your current management strategies. We'll clarify what the latest research findings and expert opinions mean in terms of starting therapy, choosing an anti-HBV agent, switching agents, and stopping therapy. You'll leave equipped to make good use of the therapeutic advances this current era has to offer.
|
Tx Reporter Newsletter |
This activity has reached its termination date and no longer offers continuing education credit.
Tx Reporter Newsletter
Currently approved treatments for chronic infection with hepatitis B virus (HBV) are limited by low rates of sustained response, side effects, and in some cases, the emergence of drug resistance. Thus, new treatments, characterized by more potent antiviral effects, less toxicity, and minimal or no risk of resistance, are needed. During the last few years, several agents have been developed that have increased potency and reduced potential for resistance, including two recently FDA-approved agents for the treatment of HBV: entecavir and peginterferon alfa-2a. In addition to these, several novel anti-HBV agents recently evaluated in phase II clinical trials, such as tenofovir, clevudine, telbivudine, pradefovir, and valtorcitabine, appear to be promising agents for the treatment of chronic hepatitis B.
|
Online Newsletter |
This activity has reached its termination date and no longer offers continuing education credit.
Online Newsletter
Through written summaries of abstracts and a linked audio discussion of those abstracts among the faculty, State of the Science in Anti-HCV Therapy will help bring a subset of the proceedings of the 56th AASLD Annual Meeting from the realm of research into the context of clinical practice. We hope that the information presented here will provide you with immediately useful strategies for improving outcomes in your patients infected with hepatitis C virus.
|
On-Demand Webcast |
This activity has reached its termination date and no longer offers continuing education credit.
On-Demand Webcast
The Circle of Experts: Strategies for Improving Outcomes of Patients with Chronic Hepatitis B Infection webcast has been developed to help clinicians stay up-to-date on the complex diagnostic, treatment, and monitoring strategies related to the therapeutic agents currently available to treat chronic hepatitis B virus (HBV) infection.
|
On-Demand Webcast |
On-Demand Webcast
Please join us for Innovative Pipeline Therapies: A Sea Change in Anti-HCV Therapy. This multidisciplinary webcast brings together experts in the management of HIV and HCV to discuss how we can apply the lessons learned in the former to the latter. We will discuss the parallels between HIV and HCV infection and therapy, and explore how future anti-HCV therapies can ride the wave begun by anti-HIV therapy. Our specific areas of exploration will include the role of multiple antiviral targets, data from early clinical trials of protease and polymerase inhibitors in HCV infection, and the potential implications of these new agents in clinical practice.
|
Tx Reporter Newsletter |
This activity has reached its termination date and no longer offers continuing education credit.
Tx Reporter Newsletter
This Tx Reporter was developed by a faculty of distinguished researchers in hepatitis C. Here you will learn about the clinical importance of anemia and ways to address its sometimes challenging management. This newsletter will also address the unique needs of special populations, such as those with co-morbid conditions and advanced disease. The advantages and disadvantages of using EPO in hepatitis C patients with anemia are described. We also provide information related to the development of an analog of ribavirin that has shown a low prevalence of anemia.
|
Interactive CD-ROM |
This activity has reached its termination date and no longer offers continuing education credit.
Click Here to Order
In this interactive CD-ROM, clinicians will apply knowledge of epidemiology, natural history, virology, and treatment to case studies representing the complex presentations and histories seen in today's clinical practice. In the course of a clinician's day, not all decision points have obvious answers. Neither will the decision points in these case studies. Our faculty panel will use these cases and decision points to discuss the controversies of HBV management. Issues will include: risk factors for progression of disease and development of hepatocellular carcinoma (HCC); immunosuppression; inactive carriers; posttreatment reactivation of infection; end-stage liver disease and liver transplant; durability of response; viral variants; liver biopsy; pregnancy and prevention of maternal transmission; and endpoints of therapy.
|
CME/CE Webcasts |
This activity has reached its termination date and no longer offers continuing education credit.
Click Here for Webcast Information
Build your mastery of anti-HBV treatment strategies in the context of emerging resistance. This webcast focuses on the nucleotide/nucleoside analogs, which complement short-term treatment with peginterferon/interferon alfa through distinct mechanisms of action that interrupt HBV replication. The goals of the curriculum are to provide an understanding of HBV replication and resistance mutations at the molecular level, and bring you up-to-date research on treatment efficacy and emerging resistance patterns.
|
Join the Care & Counsel IV Listserve | Click Here to Sign Up
We are looking forward to another year of sharing information that helps us meet the clinical challenges we face every day.
|
Interactive CME CD-ROM |
This activity has reached its termination date and no longer offers continuing education credit.
Click here to Order Your CME CD-ROM
In HIV/HBV Coinfection in Prison Systems, we will provide clinicians working within the prison setting with information about new and more efficacious drugs for the treatment of HIV/HBV coinfection. These drugs offer the potential for improved response and tolerability in coinfected patients, including those who are "difficult-to-treat" due to HBeAg-negative pre-core mutant disease, occult HBV infection, or drug resistance. Importantly, we will also demonstrate how to consider both HIV and HBV infections when making treatment decisions.
|
Monograph |
This activity has reached its termination date and no longer offers continuing education credit.
Click here to Download Your Monograph
This comprehensive CME/CE monograph will focus on the key differences in the natural history and clinical management of hepatitis B virus (HBV) infection and hepatitis C virus (HCV) infection. It will also provide new clinical insights and proven treatment strategies (including information presented during The Liver Meeting 2004) for optimizing the management of patients with HBV infection.
|
CME Audioconference |
This activity has reached its termination date and no longer offers continuing education credit.
Click here to View Webcast of Audioconference
This audioconference will review the epidemiology and natural history of hepatitis B infection, worldwide and in the United States. Risk factors for HBV infection and for disease progression will be identified, and screening and evaluation protocols discussed, including the use and interpretation of serologic and molecular diagnostic assays and liver biopsy. Faculty will also provide rationale for selecting candidates for treatment, including those in special populations, based on risk factors for disease progression and published treatment guidelines.
|
CME Newsletter |
This activity has reached its termination date and no longer offers continuing education credit.
Click here to Order the Tx Reporters
Diagnosis of Hepatitis B is the first installment in the 9-part newsletter series HBV Infection in Clinical Practice, which represents Required Course 5 in the year-long educational curriculum Advanced Certificate Program in the Management of Chronic Hepatitis B. We begin this series with a look at the epidemiology and diagnosis of hepatitis B. Here you will learn more about why the prevalence and potential sequelae of hepatitis B warrant your attention, as well as the differences among the numerous available diagnostic assays, their most cost-effective use, and how to interpret the results appropriately. This issue will also help you to identify appropriate candidates for hepatitis B screening and vaccination, and serve as a springboard for discussion in the next installment in the series, which will cover evaluation of patients for treatment.
|
Certificate Program |
This activity has reached its termination date and no longer offers continuing education credit.
Click here to View Certificate Program
The Advanced Certificate Program in the Management of Chronic Hepatitis B is a 12-month curriculum comprising intensive course work beginning March 2005. Participants completing all required courses and receiving a minimum of 18 AMA PRA Category 1 credits during this period will receive the certificate.
|
Monograph | This activity has reached its termination date and no longer offers continuing education credit.
Click here to Order the Monograph
The Clinician's Companion VII: Expert Perspectives on Contemporary Clinical Issues in Hepatitis C features the shared perspectives of experts confronting key issues, many of which are faced by clinicians in everyday practice. This information incorporates scientific advances made over the past year and their clinical implications. You will have an opportunity to learn about new findings in epidemiology, diagnosis, management of side effects associated with HCV therapies, the relationship of HCV and HCC, and strategies for managing hard-to-treat patients and those with advanced disease.
|
CME Newsletter |
This activity has reached its termination date and no longer offers continuing education credit.
Click here to Order the Tx Reporter
In this newsletter, the faculty have selected key samples from the clinical trials presented at this meeting in order to show you the nature of current research, including interim and final findings from major studies and recent preliminary data from smaller studies, as well as to suggest areas for further study. Our goal was to focus on trials representing issues that affect clinicians in their daily practice: improving response in special populations, including African Americans and HIV/HCV coinfected patients; giving prior nonresponders an opportunity for virologic response and/or histologic response through retreatment or maintenance therapy; prescribing the appropriate duration of therapy based on genotype and early virologic response; understanding the differences between the available peginterferon products; and managing acute HCV infection.
|
CME Newsletter | This activity has reached its termination date and no longer offers continuing education credit.
Click here to Order the Tx Reporter
In this newsletter, we highlight the latest findings on selected novel HCV therapies reported at The Liver Meeting 2004. In addition, we invite you to listen to expert commentary on these promising future HCV therapies. Just click on the hyperlinks next to the microphone icons throughout the text to access this commentary. This discussion is not meant to be all-inclusive, but rather encompasses some of the more promising approaches currently being evaluated for the treatment of HCV.
|
A CME Webcast |
This activity has reached its termination date and no longer offers continuing education credit.
Click here to View Webcast
If you missed the live activity at The Liver Meeting, here's another chance to catch all the latest information about peginterferon/ribavirin side effect management that came from experts in hepatology/liver disease, hematology/oncology, and psychiatry. Our experts also explore the latest developments concerning growth factors, neuroprotection, and multiple behavioral syndromes associated with interferon.
|
A CME Satellite Symposium | This activity has reached its termination date and no longer offers continuing education credit.
Click here to Order Your Webcast CD-ROM Today!
Our distinguished faculty will help you to use available therapies to improve the chance of success for your patients undergoing retreatment.
We hope to see you at this informative symposium. You will be among colleagues who share your commitment to caring for patients and providing them every means to achieve success in eradicating their HCV infection.
|
CE/CME Newsletter |
This activity has reached its termination date and no longer offers continuing education credit.
Click here to Order the Tx Reporter
Updating another well-received publication series on hepatitis C, Care & Counsel III will comprise a 4-part, 4-page newsletter series. This comprehensive CE/CME activity focuses on the crucial role that support professionals play in screening; monitoring; promoting adherence; managing side effects; and providing education, counseling, and support for your patients with hepatitis C.
|
CME Webcast |
This activity has reached its termination date and no longer offers continuing education credit.
Click here to See Meeting Information
Join us for this CME activity designed for gastroenterologists and hepatologists who treat patients with hepatitis C.
|
CME Newsletter |
This activity has reached its termination date and no longer offers continuing education credit.
Download Newsletter
In this Tx Reporter, Mark S. Sulkowski, MD, describes evolving strategies for management of PEG IFN/RBV side effects. These strategies minimize the need for dose reduction or treatment discontinuation, and can improve patient motivation. Physicians can thereby make therapy more tolerable, improve treatment adherence, and give each patient the best chance of achieving treatment goals.
|
CME Newsletter |
This activity has reached its termination date and no longer offers continuing education credit.
Download Newsletter
This CME newsletter, Monitoring of Hepatitis C Progression: Assessment of Fibrosis Using Liver Biopsy and Noninvasive Markers, describes the latest data regarding new serum markers of fibrosis. In addition, it explores the pros and cons of these tests, as well as liver biopsy, and offers some preliminary thoughts as to their most appropriate uses.
|
CME Newsletter |
This activity has reached its termination date and no longer offers continuing education credit.
Order/Download Newsletter
In this CME newsletter, HCV RNA Tests: Differences and Dilemmas, Dr. Gish explains the strengths, limitations, and best uses of available virologic tests and provides a guideline for cost-effective management of antiviral therapy. Taken together, these strategies will help increase a patient's chances for successful treatment of hepatitis C viral infection.
|
CME Meeting |
This activity has reached its termination date and no longer offers continuing education credit.
Click here to See Meeting Information
View Activity Online
Online
From Diagnosis to Treatment: The Full Spectrum of Care in Hepatitis C. This 2-hour satellite symposium builds on your current knowledge of diagnosis, treatment, and monitoring of hepatitis C to explore the latest advances and nuances of care.
|
CME Handbook |
Download Handbook
The Care & Counsel II Side Effects Management Handbook contains myriad practical tips for clinicians who treat patients for hepatitis C. This handbook is filled with strategies to help prevent and lessen the side effects of peginterferon/ribavirin. These tips will help patients feel better and stay on recommended doses throughout the course of treatment. By promoting adherence, you also promote better treatment outcomes—so download or order your copy today!
|
CME Newsletter |
This activity has reached its termination date and no longer offers continuing education credit.
Order/Download Newsletter
The discussions contained within this Tx Reporter will show you how to take advantage of today’s effective therapies, as well as strategies to optimize response in your patients. For example, the enhanced efficacy of pegylated interferon plus ribavirin can be boosted further by refining treatment protocols, such as the use of weight-based dosing and adherence strategies. Additionally, an understanding of the clinical implications of pegylation and the differences between the currently available peginterferon products will inform your treatment selection.
|
CME Newsletter |
This activity has reached its termination date and no longer offers continuing education credit.
View/Download Newsletter
Physicians who treat patients with hepatitis C face a number of new challenges, including a growing patient population and an increased demand for treatment due to the improvements in efficacy. Many of these patients will present difficult cases that require time-intensive and complicated care. Moreover, disease management requires individualized attention with tailored dosing, and aggressive monitoring and treatment of side effects. To help you meet these challenges, we have been working with a distinguished faculty to bring you this four-part, case-based Tx Reporter series. |
CME Newsletter |
This activity has reached its termination date and no longer offers continuing education credit.
View/Download Newsletter
Clinicians managing HCV-infected patients face a dilemma: how to maintain patients on the full dose of antiviral therapy for the recommended duration of time while avoiding treatment-induced anemia and its negative impact on quality of life, or possible dose reduction and discontinuation of treatment. In this newsletter, leading experts offer models of care from other disease states that physicians may successfully apply to benefit their patients on anti-HCV therapy. |
CME Newsletters |
This activity has reached its termination date and no longer offers continuing education credit.
View Newsletters Online
A five-part CME compendium that comprises The Clinician’s Companion VI. Four newsletters, representing Parts 1 through 4, feature timely reporting of the latest developments in the field, and the monograph, Part 5, will provide in-depth coverage of some of the most important issues in hepatitis C today. |
CME Newsletter |
This activity has reached its termination date and no longer offers continuing education credit.
View/Order Newsletter
Patients who stay on their medications have the best chance of responding to treatment for chronic hepatitis C. In this series, you will learn practical strategies that you and your patients can use to alleviate side effects, making treatment more tolerable. These approaches may allow you to avoid treatment discontinuation and lower the need for dose reduction—thereby increasing the likelihood of a positive outcome. |
CME Newsletter |
This activity has reached its termination date and no longer offers continuing education credit.
View/Order Newsletter
We are pleased to have assembled an outstanding faculty of experts in the treatment of hepatitis C virus (HCV) to discuss the latest developments in meeting the clinical challenge of treating HCV-infected patients with anemia. We hope that you will find this series of newsletters, New Data on Managing Anemia with Growth Factors for Patients on Anti-HCV Therapy: A Case-Based Series, interesting, thought-provoking, and educational. |
 |
This activity has reached its termination date and no longer offers continuing education credit.
Read Meeting Briefs Online
View/Download Newsletter
You’ll find a comprehensive review of the conclusions of the 2002 NIH Consensus Development Conference on Hepatitis C here. In addition, you can earn CME credit by completing an activity chaired by Dr. Willis Maddrey based on this important meeting. This CME activity will be available in mid-August, and you can pre-order it online now. |
CME Monographs |
This activity has reached its termination date and no longer offers continuing education credit.
Order/Download Monographs I, II, III
These monographs provide an opportunity for clinicians who work with HIV-infected patients to learn more about HCV, which is an increasingly relevant opportunistic infection. They provide the most current information about recent treatment advances. |
CME Monograph |
This activity has reached its termination date and no longer offers continuing education credit.
View/Order Monograph
Review the latest clinical data and examine the clinical strategies experts in the field use to ensure their patients achieve optimum results from antiviral treatment. This monograph includes practical recommendations and detailed information on patient education and support programs. |
CME CD-ROM |
This activity has reached its termination date and no longer offers continuing education credit.
Click here to order!
This CD-ROM will give you the opportunity to hear from the experts on the latest management interventions for anemia, neutropenia, and thrombocytopenia that have demonstrated improved clinical outcomes in HCV-infected patients treated with standard or pegylated interferon plus ribavirin combination therapy. |
 |
This activity has reached its termination date and no longer offers continuing education credit.
Order Newsletter
This newsletter focuses on practical strategies for preventing HAV and HBV in patients with chronic liver disease, and provides guidance on how to incorporate preventive vaccines into current practices. |
 |
This activity has reached its termination date and no longer offers continuing education credit.
View/Read Articles
Read recently published journal articles by physician assistants enrolled in “The Schering Corporation Fellowship in Liver Disease,” sponsored by the American Academy of Physician Assistants and administered by Projects In Knowledge. |
 |
This activity has reached its termination date and no longer offers continuing education credit.
View WebCast Replay
View/Order Monograph, Newsletter, or Slide Kit on CD
This innovative CME activity features the latest data on pegylated formulations of interferon, either in combination with ribavirin or as monotherapy. A distinguished faculty shares practical strategies and recommendations for tailoring these therapies to your individual patients.
 |
 |
This activity has reached its termination date and no longer offers continuing education credit.
View WebCast Replay
Broadcast to VA medical centers, clinics, and hospitals across the country. An update for medical professionals on current screening, diagnosis, treatment, and disease management strategies for patients with hepatitis C.
RealPlayerG2 format.
|
|
|
